Oppenheimer Assumes Abeona Therapeutics at Outperform, Announces Price Target of $19

Benzinga · 06/02 17:09
Oppenheimer analyst Andreas Argyrides assumes Abeona Therapeutics (NASDAQ:ABEO) with a Outperform rating and announces Price Target of $19.